Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial

Links shared publicly online about this topic.

953
total visits

Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial

Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squam

View full resource at medicalnewstoday.com

Tags: Cancer, Colorectal Cancer Medication, Head and Neck Cancer, Pharma, Phase 3 Clinical Trial, Vectibix, Amgen

Most Recently Shared on August 12, 2010 at 8:00 pm By:

MNT Cancer News

Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial http://mnt.to/3HhG #cancer

2 years ago...

Retweet

Favorite

Also Shared By:

MNT Ear, Nose Throat

MNT Clinical Trials

MNT Pharma News

Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial - QualityPoint Technologies

qualitypointtech.net — “Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone [median 11.1 months versus 9.0 months, hazard ratio 0.87 (95% CI: 0.73, 1.0” View full resource at qualitypointtech.net